LATAM Undescended Testicle Market Size & Outlook, 2026-2034
LATAM Undescended Testicle Market Insights
- Based on Reed Intelligence findings, the LATAM Undescended Testicle Market size reached USD 126.41 Million in 2025 and is expected to grow to USD 229.39 Million by 2034.
- During 2026–2034, the market is forecasted to advance at a CAGR of 6.84%.
- Surgical Treatment represented the largest share of the Treatment Type market in terms of size in 2025.
- Among the Treatment Type segments, Surgical Treatment is forecasted to achieve the highest growth and remain the most lucrative through the forecast period.
![LATAM Undescended Testicle Market Size, Share & Growth Report By [2034]](https://reedintelligence.com/uploads/charts/undescended-testicle-market-latam--143333.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, LATAM accounted for 5.72% of the global Undescended Testicle Market size.
- By 2034, United States is projected to lead the global market in terms of market size.
- Brazil is projected to emerge as the fastest-growing market in LATAM, reaching USD 88.17 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 126.41 Million |
| Market Size In 2034 | USD 229.39 Million |
| Largest segment | Surgical Treatment |
| Units | Revenue in USD Million |
| CAGR | 6.84% (2026-2034) |
| Segmnetation Covered | |
| LATAM |
|
| Treatment Type |
|
| Diagnosis Method |
|
| End-Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
LATAM Undescended Testicle Market Country 2026-2034 (USD Million)
| LATAM | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil | XX.x | XX.x | XX.x | 48.04 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Mexico | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Argentina | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Colombia | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Chile | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
LATAM Undescended Testicle Market Treatment Type 2026-2034 (USD Million)
| Treatment Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgical Treatment | XX.x | XX.x | XX.x | 71.17 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hormonal Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
LATAM Undescended Testicle Market Diagnosis Method 2026-2034 (USD Million)
| Diagnosis Method | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical Examination | XX.x | XX.x | XX.x | 57.48 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ultrasound Imaging | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| MRI | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
LATAM Undescended Testicle Market End-Use 2026-2034 (USD Million)
| End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 60.08 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Pediatric Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ambulatory Surgical Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.